Hyperplasia, Prostate Cancer
Conditions
Keywords
Prostate Cancer, Hyperplasia - BPH, FACS, Prostate Cancer, Hyperplasia - BPH, Malignancy
Brief summary
Early detection of prostrate cancer and development of metastases. The research will attempt to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the CellScan instrument. The test is based on measurement of cellular changes in response to the specific prostate antigen, PSA.
Interventions
None listed
Sponsors
Ziv Hospital
Study design
Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
60 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
Experimental group : Males between the ages of 60-90 years, with medical diagnosis of prostate cancer according to both clinical and hematological examinations, before receiving any medical treatment. Control Group 1: Males between the ages of 60-90 years, with diagnosed benign prostate hyperplasia -BPH. Control Group 2: Males between the ages of 60-90 years, medically diagnosed as healthy. Control Group 3: Males between the ages of 60-90 years, medically diagnosed with another form of cancer, not prostate.
Exclusion criteria
Experimental group: Other known cancer or systemic infection. Control Group 1: Other known cancer or systemic infection. Control Group 2:Past hematological disorders nor cancer growth history. other known systemic infection, nor urinary tract infection. Patients hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract infections. Control Group 3:Other known systemic infection, nor urinary tract infection. \-
Countries
Israel
Contacts
Primary ContactNina Kucherski, MD
Backup ContactYihia Johari, MD
Outcome results
None listed